The Core of Innovation is Collaboration

Bringing innovative viral-based therapies to patients requires the synergistic focus of diverse collaborators who can marry creativity with the rigor of clinical development. Our R&D scientists draw on broad expertise in viral engineering, immunology, oncology, gene editing and vector development to create targeted applications for viral-based therapies. Most importantly, our scientists do not work in a vacuum. At Vyriad, the conversations between our partners, our R&D team and our manufacturing experts are essential to an innovation engine that develops novel in vivo delivery platforms with groundbreaking, real world applications.

Learning From Success

We have proven expertise engineering and developing viruses that deliver life-changing therapies. Our founding research and development of oncolytic viruses gives our team broad expertise in optimizing viral delivery platforms for cell-specific targeting, stability and efficiency. Since our founding, we have developed hundreds of candidate viruses, and know how to select and engineer viral candidates best suited to targeted therapeutic applications and patient populations. Now, we are transferring that expertise to the development of viral vectors for gene editing and in vivo CAR T cell therapy, enabling the next generation of durable and targeted genetic medicines.